At the time of writing, Verrica Pharmaceuticals Inc [VRCA] stock is trading at $0.99, up 11.56%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRCA shares have gain 14.68% over the last week, with a monthly amount drifted -34.44%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Verrica Pharmaceuticals Inc [NASDAQ: VRCA] stock has seen the most recent analyst activity on November 06, 2024, when H.C. Wainwright downgraded its rating to a Neutral. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on November 05, 2024. On July 25, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $10 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $10 on March 22, 2023. RBC Capital Mkts upgraded its rating to a Outperform and raised its price target to $11 on February 13, 2023. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on May 25, 2022, and downed its price target to $4. In a note dated May 14, 2021, RBC Capital Mkts initiated an Outperform rating and provided a target price of $19 on this stock.
For the past year, the stock price of Verrica Pharmaceuticals Inc fluctuated between $0.70 and $11.41. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Verrica Pharmaceuticals Inc [NASDAQ: VRCA] shares were valued at $0.99 at the most recent close of the market. An investor can expect a potential return of 1112.12% based on the average VRCA price forecast.
Analyzing the VRCA fundamentals
According to Verrica Pharmaceuticals Inc [NASDAQ:VRCA], the company’s sales were 9.21M for trailing twelve months, which represents an -161.06% plunge. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -8.16%, Pretax Profit Margin comes in at -9.23%, and Net Profit Margin reading is -9.23%. To continue investigating profitability, this company’s Return on Assets is posted at -2.58, Equity is 13.04 and Total Capital is -6.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8633 points at the first support level, and at 0.7367 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1033, and for the 2nd resistance point, it is at 1.2167.
Ratios To Look Out For
It is important to note that Verrica Pharmaceuticals Inc [NASDAQ:VRCA] has a current ratio of 1.34. On the other hand, the Quick Ratio is 1.22, and the Cash Ratio is 1.09. Considering the valuation of this stock, the price to sales ratio is 4.90.
Transactions by insiders
Recent insider trading involved Hayes Christopher G., CHIEF LEGAL OFFICER, that happened on Aug 26 ’24 when 26183.0 shares were sold. CHIEF LEGAL OFFICER, Hayes Christopher G. completed a deal on Aug 27 ’24 to sell 9530.0 shares. Meanwhile, Chief Medical Officer Goldenberg Gary sold 9888.0 shares on Aug 26 ’24.
